{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:10:23Z","timestamp":1787728223755,"version":"build-2784847793"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022JEBP88,"],"award-info":[{"award-number":["PRIN 2022JEBP88,"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia"],"award-info":[{"award-number":["PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Defects of the gut epithelial barrier and counter-regulatory mechanisms are a prerequisite for the onset of intestinal inflammation in patients with inflammatory bowel diseases (IBD). Elevated levels of Smad7, an inhibitor of TGF-\u03b21, in both epithelial and immune cells have been associated with the pathological processes observed in IBD. We aim to determine the relevance of Smad7 expression in the epithelial compartment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We generated mice overexpressing Smad7 in the gut epithelium (Smad7TgCre\n                      <jats:sup>+<\/jats:sup>\n                      ) and monitored pathology development. Inflammatory cell infiltration was assessed using multiplex immunofluorescence and flow cytometry. To investigate the molecular mechanisms underlying ileal damage, we performed spatial transcriptomics on frozen ileal samples and metabolomics on intestinal epithelial cells (IECs) from Smad7TgCre\n                      <jats:sup>+<\/jats:sup>\n                      and control mice. The impact of adenosine on Mucin-2 expression was evaluated through both in vitro and in vivo approaches. Finally, we evaluated the protein expression of CD73 and Smad7 in ileal tissue from Crohn\u2019s disease (CD) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Smad7TgCre\n                      <jats:sup>+<\/jats:sup>\n                      mice developed spontaneous terminal ileitis, which was characterized by villus shortening and widening, mucus depletion, increased intestinal permeability, and infiltration of CD8\u2009+\u2009T cells. By integrating spatial transcriptomics and metabolomics data, we demonstrated that Smad7TgCre\n                      <jats:sup>+<\/jats:sup>\n                      mice exhibited altered expression of enzymes involved in purine metabolism, particularly CD73, the key enzyme responsible for adenosine production. Consequently, these mice produced lower levels of adenosine, and oral adenosine administration restored mucus production and alleviated the ileal pathology. Lastly, we observed that in the inflamed ileum of CD patients, elevated Smad7 levels were correlated with decreased CD73 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data indicate that Smad7 overexpression in IECs is sufficient to promote ileal mucosal damage, which is linked to the impairment of purine metabolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-026-01224-3","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:26:44Z","timestamp":1771338404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intestinal epithelial Smad7 drives purine metabolic dysregulation and ileal inflammation"],"prefix":"10.1186","volume":"33","author":[{"given":"Federica","family":"Laudisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia Alberto","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Claudio","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Monasterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Maria","family":"Sommella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ortenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Sigismondo","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pacifico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Melaiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"De Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"D\u2019Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Stolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Javier","family":"Villablanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066\u201378. https:\/\/doi.org\/10.1056\/NEJMra0804647.","journal-title":"N Engl J Med"},{"key":"1224_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri1132","volume":"3","author":"G Bouma","year":"2003","unstructured":"Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521\u201333. https:\/\/doi.org\/10.1038\/nri1132.","journal-title":"Nat Rev Immunol"},{"key":"1224_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","volume":"474","author":"KJ Maloy","year":"2011","unstructured":"Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298\u2013306. https:\/\/doi.org\/10.1038\/nature10208.","journal-title":"Nature"},{"key":"1224_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119\u201324. https:\/\/doi.org\/10.1038\/nature11582.","journal-title":"Nature"},{"key":"1224_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00996-7","volume":"13","author":"JC Ntunzwenimana","year":"2021","unstructured":"Ntunzwenimana JC, Boucher G, Paquette J, Gosselin H, Alikashani A, Morin N, et al. Functional screen of inflammatory bowel disease genes reveals key epithelial functions. Genome Med. 2021;13:181. https:\/\/doi.org\/10.1186\/s13073-021-00996-7.","journal-title":"Genome Med"},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41588-022-01156-2","volume":"54","author":"A Sazonovs","year":"2022","unstructured":"Sazonovs A, Stevens CR, Venkataraman GR, Yuan K, Avila B, Abreu MT, et al. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn\u2019s disease susceptibility. Nat Genet. 2022;54:1275\u201383. https:\/\/doi.org\/10.1038\/s41588-022-01156-2.","journal-title":"Nat Genet"},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","volume":"55","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liu R, Gao H, Jung S, Gao X, Sun R, et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet. 2023;55:796\u2013806. https:\/\/doi.org\/10.1038\/s41588-023-01384-0.","journal-title":"Nat Genet"},{"key":"1224_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665530","author":"G Monteleone","year":"2025","unstructured":"Monteleone G, Calisi C, Salvatori S, Marafini I. Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1665530.","journal-title":"Front Immunol"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/ng.221","volume":"40","author":"A Franke","year":"2008","unstructured":"Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319\u201323. https:\/\/doi.org\/10.1038\/ng.221.","journal-title":"Nat Genet"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"E-O Glocker","year":"2009","unstructured":"Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Sch\u00e4ffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033\u201345. https:\/\/doi.org\/10.1056\/NEJMoa0907206.","journal-title":"N Engl J Med"},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","volume":"75","author":"R K\u00fchn","year":"1993","unstructured":"K\u00fchn R, L\u00f6hler J, Rennick D, Rajewsky K, M\u00fcller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263\u201374. https:\/\/doi.org\/10.1016\/0092-8674(93)80068-P.","journal-title":"Cell"},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1097\/MIB.0000000000000872","volume":"22","author":"AL Guerrerio","year":"2016","unstructured":"Guerrerio AL, Frischmeyer-Guerrerio PA, Huang C, Wu Y, Haritunians T, McGovern DPB, et al. Increased prevalence of inflammatory bowel disease in patients with mutations in genes encoding the receptor subunits for TGF\u03b2. Inflamm Bowel Dis. 2016;22:2058\u201362. https:\/\/doi.org\/10.1097\/MIB.0000000000000872.","journal-title":"Inflamm Bowel Dis"},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-\u03b21 gene results in multifocal inflammatory disease. Nature. 1992;359:693\u20139. https:\/\/doi.org\/10.1038\/359693a0.","journal-title":"Nature"},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90:770\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.770.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1224_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/gut.49.2.190","volume":"49","author":"K-B Hahm","year":"2001","unstructured":"Hahm K-B, Im Y-H, Parks TW, Park S-H, Markowitz S, Jung H-Y, et al. Loss of transforming growth factor \u03b2 signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 2001;49:190\u20138. https:\/\/doi.org\/10.1136\/gut.49.2.190.","journal-title":"Gut"},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50:924\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","journal-title":"Immunity"},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2004.07.008","volume":"25","author":"G Monteleone","year":"2004","unstructured":"Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-\u03b2-mediated negative regulation of gut inflammation. Trends Immunol. 2004;25:513\u20137. https:\/\/doi.org\/10.1016\/j.it.2004.07.008.","journal-title":"Trends Immunol"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0092-8674(00)80303-7","volume":"89","author":"H Hayashi","year":"1997","unstructured":"Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGF\u03b2 receptor and functions as an antagonist of TGF\u03b2 signaling. Cell. 1997;89:1165\u201373. https:\/\/doi.org\/10.1016\/S0092-8674(00)80303-7.","journal-title":"Cell"},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/39369","volume":"389","author":"A Nakao","year":"1997","unstructured":"Nakao A, Afrakhte M, Morn A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGF\u03b2-inducible antagonist of TGF-\u03b2 signalling. Nature. 1997;389:631\u20135. https:\/\/doi.org\/10.1038\/39369.","journal-title":"Nature"},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","volume":"32","author":"MA Travis","year":"2014","unstructured":"Travis MA, Sheppard D. TGF-\u03b2 activation and function in immunity. Annu Rev Immunol. 2014;32:51\u201382. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120257.","journal-title":"Annu Rev Immunol"},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0002-9440(10)63853-9","volume":"162","author":"PL Beck","year":"2003","unstructured":"Beck PL, Rosenberg IM, Xavier RJ, Koh T, Wong JF, Podolsky DK. Transforming growth factor-\u03b2 mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol. 2003;162:597\u2013608. https:\/\/doi.org\/10.1016\/S0002-9440(10)63853-9.","journal-title":"Am J Pathol"},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.1365-2249.2003.02250.x","volume":"134","author":"B Del Zotto","year":"2003","unstructured":"Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, Boirivant M. TGF- \u03b2 1 production in inflammatory bowel disease: differing production patterns in Crohn\u2019s disease and ulcerative colitis. Clin Exp Immunol. 2003;134:120\u20136. https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02250.x.","journal-title":"Clin Exp Immunol"},{"key":"1224_CR23","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","volume":"131","author":"M Boirivant","year":"2006","unstructured":"Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-\u03b21\u2013mediated suppression of colitis. Gastroenterology. 2006;131:1786\u201398. https:\/\/doi.org\/10.1053\/j.gastro.2006.09.016.","journal-title":"Gastroenterology"},{"key":"1224_CR24","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1074\/jbc.M303654200","volume":"279","author":"G Monteleone","year":"2004","unstructured":"Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M, et al. A failure of transforming growth factor-\u03b21 negative regulation maintains sustained NF-\u03baB activation in gut inflammation. J Biol Chem. 2004;279:3925\u201332. https:\/\/doi.org\/10.1074\/jbc.M303654200.","journal-title":"J Biol Chem"},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1172\/JCI12821","volume":"108","author":"G Monteleone","year":"2001","unstructured":"Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-\u03b21 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601\u20139. https:\/\/doi.org\/10.1172\/JCI12821.","journal-title":"J Clin Invest"},{"key":"1224_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01854","author":"S Sedda","year":"2018","unstructured":"Sedda S, Franz\u00e8 E, Bevivino G, Di Giovangiulio M, Rizzo A, Colantoni A, et al. Reciprocal regulation between Smad7 and Sirt1 in the gut. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01854.","journal-title":"Front Immunol"},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/gene.20042","volume":"39","author":"F El Marjou","year":"2004","unstructured":"El Marjou F, Janssen K, Hung\u2010Junn Chang B, Li M, Hindie V, Chan L, et al. Tissue\u2010specific and inducible Cre\u2010mediated recombination in the gut epithelium. Genesis. 2004;39:186\u201393. https:\/\/doi.org\/10.1002\/gene.20042.","journal-title":"Genesis"},{"key":"1224_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2004.11.063","volume":"128","author":"T Dohi","year":"2005","unstructured":"Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128:411\u201323. https:\/\/doi.org\/10.1053\/j.gastro.2004.11.063.","journal-title":"Gastroenterology"},{"key":"1224_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/labinvest.2017.6","volume":"97","author":"L Van den Bossche","year":"2017","unstructured":"Van den Bossche L, Borsboom D, Devriese S, Van Welden S, Holvoet T, Devisscher L, et al. Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn\u2019s disease-like ileitis. Lab Invest. 2017;97:519\u201329. https:\/\/doi.org\/10.1038\/labinvest.2017.6.","journal-title":"Lab Invest"},{"key":"1224_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20331","author":"N Sakamoto","year":"2017","unstructured":"Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, et al. BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife. 2017. https:\/\/doi.org\/10.7554\/eLife.20331.","journal-title":"Elife"},{"key":"1224_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0016-5085(97)70128-8","volume":"112","author":"G Monteleone","year":"1997","unstructured":"Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al. Interleukin 12 is expressed and actively released by Crohn\u2019s disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169\u201378. https:\/\/doi.org\/10.1016\/S0016-5085(97)70128-8.","journal-title":"Gastroenterology"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1572-0241.2000.02241.x","volume":"95","author":"J O\u2019Brien","year":"2000","unstructured":"O\u2019Brien J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:1859\u201361. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.02241.x.","journal-title":"Am J Gastroenterol"},{"key":"1224_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41586-022-05308-6","volume":"611","author":"LM Sanmarco","year":"2022","unstructured":"Sanmarco LM, Chao C-C, Wang Y-C, Kenison JE, Li Z, Rone JM, et al. Identification of environmental factors that promote intestinal inflammation. Nature. 2022;611:801\u20139. https:\/\/doi.org\/10.1038\/s41586-022-05308-6.","journal-title":"Nature"},{"key":"1224_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","volume":"36","author":"D Boison","year":"2019","unstructured":"Boison D, Yegutkin GG. Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell. 2019;36:582\u201396. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.007.","journal-title":"Cancer Cell"},{"key":"1224_CR35","doi-asserted-by":"publisher","first-page":"G904","DOI":"10.1152\/ajpgi.00015.2012","volume":"303","author":"M Fausther","year":"2012","unstructured":"Fausther M, Sheung N, Saiman Y, Bansal MB, Dranoff JA. Activated hepatic stellate cells upregulate transcription of ecto-5\u2032-nucleotidase\/CD73 via specific SP1 and SMAD promoter elements. Am J Physiol Gastrointest Liver Physiol. 2012;303:G904\u201314. https:\/\/doi.org\/10.1152\/ajpgi.00015.2012.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1224_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050381","volume":"13","author":"M Stepanova","year":"2024","unstructured":"Stepanova M, Aherne CM. Adenosine in intestinal epithelial barrier function. Cells. 2024;13:381. https:\/\/doi.org\/10.3390\/cells13050381.","journal-title":"Cells"},{"key":"1224_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02558-8","volume":"18","author":"F Zorzi","year":"2020","unstructured":"Zorzi F, Calabrese E, Di Fusco D, De Cristofaro E, Biancone L, Casella S, et al. High Smad7 in the early post-operative recurrence of Crohn\u2019s disease. J Transl Med. 2020;18:395. https:\/\/doi.org\/10.1186\/s12967-020-02558-8.","journal-title":"J Transl Med"},{"key":"1224_CR38","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/febs.13771","volume":"283","author":"JM Blander","year":"2016","unstructured":"Blander JM. Death in the intestinal epithelium\u2014basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720\u201330. https:\/\/doi.org\/10.1111\/febs.13771.","journal-title":"FEBS J"},{"key":"1224_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/jcp.2004.021840","volume":"58","author":"DSA Sanders","year":"2005","unstructured":"Sanders DSA. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn\u2019s disease: figure 1. J Clin Pathol. 2005;58:568\u201372. https:\/\/doi.org\/10.1136\/jcp.2004.021840.","journal-title":"J Clin Pathol"},{"key":"1224_CR40","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI119447","volume":"99","author":"GR Strohmeier","year":"1997","unstructured":"Strohmeier GR, Lencer WI, Patapoff TW, Thompson LF, Carlson SL, Moe SJ, et al. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest. 1997;99:2588\u2013601. https:\/\/doi.org\/10.1172\/JCI119447.","journal-title":"J Clin Invest"},{"key":"1224_CR41","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.4049\/jimmunol.180.6.4246","volume":"180","author":"NA Louis","year":"2008","unstructured":"Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-\u03b1A by CD73: implications for mucosal inflammation. J Immunol. 2008;180:4246\u201355. https:\/\/doi.org\/10.4049\/jimmunol.180.6.4246.","journal-title":"J Immunol"},{"key":"1224_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/260983","volume":"2012","author":"MS Bynoe","year":"2012","unstructured":"Bynoe MS, Waickman AT, Mahamed DA, Mueller C, Mills JH, Czopik A. CD73 is critical for the resolution of murine colonic inflammation. J Biomed Biotechnol. 2012;2012:1\u201313. https:\/\/doi.org\/10.1155\/2012\/260983.","journal-title":"J Biomed Biotechnol"},{"key":"1224_CR43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI15337","volume":"110","author":"K Synnestvedt","year":"2002","unstructured":"Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5\u2032-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Investig. 2002;110:993\u20131002. https:\/\/doi.org\/10.1172\/JCI15337.","journal-title":"J Clin Investig"},{"key":"1224_CR44","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/eji.201141512","volume":"41","author":"FS Regateiro","year":"2011","unstructured":"Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, et al. Generation of anti\u2010inflammatory adenosine by leukocytes is regulated by TGF\u2010\u03b2. Eur J Immunol. 2011;41:2955\u201365. https:\/\/doi.org\/10.1002\/eji.201141512.","journal-title":"Eur J Immunol"},{"key":"1224_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbrc.2020.01.108","volume":"524","author":"S Anzai","year":"2020","unstructured":"Anzai S, Kawamoto A, Nagata S, Takahashi J, Kawai M, Kuno R, et al. TGF-\u03b2 promotes fetal gene expression and cell migration velocity in a wound repair model of untransformed intestinal epithelial cells. Biochem Biophys Res Commun. 2020;524:533\u201341. https:\/\/doi.org\/10.1016\/j.bbrc.2020.01.108.","journal-title":"Biochem Biophys Res Commun"},{"key":"1224_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pharmthera.2008.08.010","volume":"120","author":"L Antonioli","year":"2008","unstructured":"Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther. 2008;120:233\u201353. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.08.010.","journal-title":"Pharmacol Ther"},{"key":"1224_CR47","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/ijms15022024","volume":"15","author":"S Sheth","year":"2014","unstructured":"Sheth S, Brito R, Mukherjea D, Rybak L, Ramkumar V. Adenosine receptors: expression, function and regulation. Int J Mol Sci. 2014;15:2024\u201352. https:\/\/doi.org\/10.3390\/ijms15022024.","journal-title":"Int J Mol Sci"},{"key":"1224_CR48","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1096\/fj.04-1964fje","volume":"18","author":"N McNamara","year":"2004","unstructured":"McNamara N, Gallup M, Khong A, Sucher A, Maltseva I, Fahy JV, et al. Adenosine up\u2010regulation of the mucin gene, MU2, in asthma. FASEB J. 2004;18:1770\u20132. https:\/\/doi.org\/10.1096\/fj.04-1964fje.","journal-title":"FASEB J"},{"key":"1224_CR49","doi-asserted-by":"publisher","first-page":"C799","DOI":"10.1152\/ajpcell.1989.256.4.C799","volume":"256","author":"GH Moser","year":"1989","unstructured":"Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol Cell Physiol. 1989;256:C799-806. https:\/\/doi.org\/10.1152\/ajpcell.1989.256.4.C799.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1224_CR50","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cellsig.2016.02.010","volume":"28","author":"AA Welihinda","year":"2016","unstructured":"Welihinda AA, Kaur M, Greene K, Zhai Y, Amento EP. The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell Signal. 2016;28:552\u201360. https:\/\/doi.org\/10.1016\/j.cellsig.2016.02.010.","journal-title":"Cell Signal"},{"key":"1224_CR51","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14549","volume":"28","author":"W Hu","year":"2024","unstructured":"Hu W, Cheng L, Zhao J, Wu Y, Lin Y, Yin J. Purine metabolite inosine induced by transforming growth factor-\u03b2 promotes epithelial-mesenchymal transition in colorectal cancer. Oncol Lett. 2024;28:416. https:\/\/doi.org\/10.3892\/ol.2024.14549.","journal-title":"Oncol Lett"},{"key":"1224_CR52","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2011.290","volume":"20","author":"G Monteleone","year":"2012","unstructured":"Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn\u2019s disease. Mol Ther. 2012;20:870\u20136. https:\/\/doi.org\/10.1038\/mt.2011.290.","journal-title":"Mol Ther"},{"key":"1224_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","volume":"372","author":"G Monteleone","year":"2015","unstructured":"Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease. N Engl J Med. 2015;372:1104\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1407250.","journal-title":"N Engl J Med"},{"key":"1224_CR54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/apt.12051","volume":"36","author":"F Zorzi","year":"2012","unstructured":"Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide ( <scp>GED<\/scp> 0301) does not increase the risk of small bowel strictures in Crohn\u2019s disease. Aliment Pharmacol Ther. 2012;36:850\u20137. https:\/\/doi.org\/10.1111\/apt.12051.","journal-title":"Aliment Pharmacol Ther"},{"key":"1224_CR55","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/apt.13526","volume":"43","author":"G Monteleone","year":"2016","unstructured":"Monteleone G, Di Sabatino A, Ardizzone S, Pallone F, Usiskin K, Zhan X, et al. Impact of patient characteristics on the clinical efficacy of mongersen (GED\u20100301), an oral Smad7 antisense oligonucleotide, in active Crohn\u2019s disease. Aliment Pharmacol Ther. 2016;43:717\u201324. https:\/\/doi.org\/10.1111\/apt.13526.","journal-title":"Aliment Pharmacol Ther"},{"key":"1224_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-021-00482-x","volume":"35","author":"I Marafini","year":"2021","unstructured":"Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, et al. A pharmacological batch of Mongersen that downregulates Smad7 is effective as induction therapy in active Crohn\u2019s disease: a phase II, open-label study. BioDrugs. 2021;35:325\u201336. https:\/\/doi.org\/10.1007\/s40259-021-00482-x.","journal-title":"BioDrugs"},{"key":"1224_CR57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","volume":"115","author":"BE Sands","year":"2020","unstructured":"Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Fr\u00e9d\u00e9ric Colombel J, et al. Mongersen (GED-0301) for active Crohn\u2019s disease: results of a phase 3 study. Am J Gastroenterol. 2020;115:738\u201345. https:\/\/doi.org\/10.14309\/ajg.0000000000000493.","journal-title":"Am J Gastroenterol"},{"key":"1224_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/nat.2021.0089","volume":"32","author":"L Arrico","year":"2022","unstructured":"Arrico L, Stolfi C, Marafini I, Monteleone G, Demartis S, Bellinvia S, et al. Inhomogeneous diastereomeric composition of Mongersen antisense phosphorothioate oligonucleotide preparations and related pharmacological activity impairment. Nucleic Acid Ther. 2022;32:312\u201320. https:\/\/doi.org\/10.1089\/nat.2021.0089.","journal-title":"Nucleic Acid Ther"},{"key":"1224_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01407","author":"E Troncone","year":"2018","unstructured":"Troncone E, Marafini I, Stolfi C, Monteleone G. Transforming growth factor-\u03b21\/Smad7 in intestinal immunity, inflammation, and cancer. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01407.","journal-title":"Front Immunol"},{"key":"1224_CR60","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/ibd\/izy062","volume":"24","author":"R Izzo","year":"2018","unstructured":"Izzo R, Bevivino G, De Simone V, Sedda S, Monteleone I, Marafini I, et al. Knockdown of Smad7 with a specific antisense oligonucleotide attenuates colitis and colitis-driven colonic fibrosis in mice. Inflamm Bowel Dis. 2018;24:1213\u201324. https:\/\/doi.org\/10.1093\/ibd\/izy062.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-026-01224-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:26:45Z","timestamp":1771338405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-026-01224-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1186\/s12929-026-01224-3","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experimental procedures were approved by the animal ethics committee under Italian legislation on animal experimentation (authorization number A69A0.69) and in compliance with European Union rules (2010\/63\/UE). The human studies were approved by the local ethics committee (protocol number: R.S. 58.23), and each patient gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Giovanni Monteleone served as a consultant for First Wave BioPharma and Giuliani SpA and as a speaker for Takeda, Eli Lilly, Abbvie, Galapagos, and Pfizer and filed a patent related to the treatment of inflammatory bowel diseases with Smad7 antisense oligonucleotides. The other authors declare no commercial or financial conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}